Valeant Pharma (NYSE: VRX) announced that its Audit and Risk Committee and the full Board of Directors have reviewed the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Conference Calls Corporate News FDA Hot Corp. News Litigation Trader Talk

Valeant Pharma (VRX) Halts the Bloodletting Following Conference CallOctober 26, 2015 1:03 PM Valeant (VRX) CC Seen as Step Forward at BMO Capital But More Needed to Rebuild Investor ConfidenceOctober 26, 2015 10:35 AM Mizuho Provides Quick Thoughts on Valeant (VRX) Slides/CallOctober 26, 2015 9:14 AM Valeant Pharma (VRX) says ad hoc committee will review issues brought up in today's WSJOctober 26, 2015 8:43 AM Valeant Pharma (VRX) Regains Some Early Losses as Conference Call StartsOctober 26, 2015 8:09 AM Valeant Pharma (VRX) Files Presentation on Philidor; Says No Evidence of Illegal Activity To-DateOctober 26, 2015 7:28 AM Valeant Pharma (VRX) Releases Slides Ahead of Investor Conference CallOctober 26, 2015 7:28 AM WSJ Highlights More 'Smoke' at Valeant Pharma (VRX) Ahead of Conference CallOctober 26, 2015 6:39 AM Valeant Pharmaceuticals Confirms Appropriateness Of Accounting, Appoints Ad Hoc Board Committee To Review PhilidorOctober 26, 2015 6:15 AM Valeant Pharma (VRX) Adds ValueAct's Morfit as DirectorOctober 26, 2015 6:13 AM Form 10-Q Valeant Pharmaceuticals For: Sep 30October 26, 2015 6:07 AM Valeant Pharmaceuticals Announces The Addition Of G. Mason Morfit To Its Board Of DirectorsOctober 26, 2015 6:00 AM